HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Treatment Claims Linked To Depression Drug Found In Supplements

This article was originally published in The Rose Sheet

Executive Summary

FDA warns MA Labs and Jack B Goods about online claims that their tianeptine-containing products treat opioid use disorder, pain and anxiety and other violative and unproven claims. CDC reports a jump in poison control center reports on tianeptine, which is approved outside the US to treat depression.

You may also be interested in...



House Members Take STAND On Tianeptine As ‘Unregulated Drug’ In Supplements

Reps. Panetta and Pfluger introduce Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act to make tianeptine a schedule III controlled substance a day after FDA posts latest alert to warn consumers against using products containing ingredient known as “gas station heroin.”

Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation

Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.

Unapproved Depression Drug Remains Available In US In Supplements To Treat Opioid Addiction

CSPI says FDA has warned companies about tianeptine, which stimulates opioid receptors and may trigger addiction and withdrawal symptoms. But “tianeptine products continue to be widely available in Alabama and online.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel